The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
March 7th 2024
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
FDA Lifts Partial Hold for Phase 2 Trial of R/R Hodgkin Lymphoma Therapy
July 8th 2020FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.
Read More
NCCN Patient Guidelines Highlight Side Effects of Immunotherapy, CAR T-Cell Therapy
July 3rd 2020Immunotherapy and chimeric antigen receptor (CAR) T-cell therapy are new and important treatments revolutionizing care of some cancers; however, their side effects can be very different than what is seen in traditional approaches, such as chemotherapy.
Read More
COVID-19 Raises Difficult Challenges for CAR T-Cell Therapy Administration
June 27th 2020Patients with B-cell non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia can benefit greatly from chimeric antigen receptor (CAR) T-cell therapy, but providing that therapy has become much more difficult in the age of coronavirus disease 2019 (COVID-19).
Read More
Selinexor Approved Under Accelerated Pathway to Treat DLBCL
June 24th 2020The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The oral treatment is to be used after at least 2 lines of systemic therapy.
Read More
Rituximab, Anthracycline Have Benefits in Oldest Patients With Diffuse Large B-Cell Lymphoma
June 20th 2020Most studies of patients with diffuse large B-cell lymphoma do not include those over the age of 80. However, a new study says those patients, like younger patients, benefit from receiving rituximab and anthracycline in their chemotherapy regimens when possible.
Read More
Newly Identified MicroRNA Signatures Could Reshape Pediatric ALL Diagnosis, Study Says
June 19th 2020Diagnosis pediatric acute lymphoblastic leukemia (ALL) can be a costly and cumbersome experience. New research has identified microRNA signatures that could simplify the process of diagnosis and classifying the cancer.
Read More
CAG Regimen Shows Strong Results as Salvage Therapy in T-ALL
June 13th 2020Patients with relapsed/refractory T-cell lymphoblastic leukemia face poor outcomes, and are generally treated by salvage therapy followed by allogeneic hematopoietic stem cell transplant. A new study suggests an optimal option for salvage therapy.
Read More
Review Finds Questions Remaining About Ibrutinib Dose Modification in CLL
June 13th 2020A subset of patients taking ibrutinib as a therapy for chronic lymphocytic leukemia (CLL) will require dose modifications. A new study attempts to evaluate the impacts of such changes, though the authors find many questions remain unsolved.
Read More
New Tool Aims for Accurate Risk Assessment in AML, Even With Gaps in Data
June 6th 2020Accurate risk assessment is a highly technical process for patients with acute myeloid leukemia (AML). A new tool could help make such assessments available even when patients can’t get to a specialty care center.
Read More
Biomarker Advances Bring New Hope of Targeted PTCL Therapy
June 6th 2020Peripheral T-cell lymphoma (PTCL) has been a challenging nemesis for scientists, in large part because it is a widely heterogeneous disease. However, new research into biomarkers for the cancer may lead to better therapies soon.
Read More
Case Study Highlights Potential Link Between TKIs and Lymphoplasmacytic Lymphoma
May 15th 2020Patients who are treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia are at a higher risk of a secondary malignancy. A new case study suggest the list of potential secondary malignancies should include lymphoplasmacytic lymphoma.
Read More
Nivolumab-Based First-Line Treatment Is Effective in Treating Hodgkin Lymphoma, Study Finds
May 9th 2020Nivolumab-based first-line treatment is highly effective in patients with early-stage unfavorable classic Hodgkin lymphoma, according to results from the Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma trial published in JAMA Oncology.
Read More
New Research Shows Real-World Track Record of Common CLL Therapies
April 24th 2020A new study based on treatment of patients with chronic lymphocytic leukemia (CLL) in mostly community settings challenges earlier findings about the superiority of a common therapeutic approach and also makes a strong case for ibrutinib.
Read More
Dr Karl Kilgore Outlines Challenges of Collecting Real-World Data on CAR T-Cell Therapy
March 18th 2020Several challenges arise when using real-world data derived from claims to study the impacts of CAR T-cell therapy on Medicare patients, said Karl Kilgore, PhD, senior research analyst at Avalere Health.
Watch
Patient Care Must Be an Ongoing Collaboration That Includes Multifaceted Concerns, Panel Says
March 8th 2020The theme of ACCC Immediate Past President Ali McBride, PharmD, MS, BPS, BCOP, for his 2019-2020 term was “Collaborate. Educate. Compensate: A Prescription for Sustainable Cancer Care Delivery.” Nowhere was that more evident than in the panel discussion he led on day 2 of this year’s annual conference.
Read More
Dr Karl Kilgore Discusses Benefits of CAR T-Cell Therapy for Medicare Patients
February 27th 2020Medicare patients' health care utilization, including hospitalizations and emergency department visits, decreased after CAR T-cell therapy, said Karl Kilgore, PhD, senior research analyst at Avalere Health.
Watch